This week
Suggest a nameObligation Marketing for AI Builders
The 7-Rung LadderThe 8-Type TaxonomyWrapper or WinnerThe Sample ColumnThe Signal
Updated through the day. Every headline links straight to the source. The two lines underneath are ours.
Solid proof of concept for using LLMs in computational biology. Codex excels at parsing and generating code for genome search, ChatGPT handles reasoning about which candidates to prioritize. This is the kind of vertical application that matters. If you're building scientific tools on LLMs, this shows the economics and feasibility. Not a model release, but a real workflow win.
Pande's argument that open, shared datasets beat walled-off proprietary ones is a direct challenge to how most biotech AI startups currently operate, hoarding data as a moat. It's also a quiet admission that mega-fund biotech investing didn't produce proportionate returns, hence the move to smaller, more concentrated bets. Worth reading for anyone raising in AI-bio: the data strategy pitch just got harder to sell to this class of investor.
Solid applied ML work for oncology biomarker prediction, with real benchmark gains on TCGA and PDX data. Relevant to biotech-focused builders and investors watching the perturbation-modeling space, but it is a niche academic advance rather than something that reshapes strategy this week.
This is a domain-specific foundation model that solves the heterogeneity problem in cell biology data. If you're building medical AI tooling around immune profiling, this reduces your pretraining burden. The open-weight release matters: you're not dependent on a closed API for a critical scientific use case.
Drug discovery has been one of AI's most hyped verticals for a decade, and honest stock-taking pieces like this are useful precisely because they cut through vendor claims from Insilico, Recursion, and others. If the piece is skeptical about near-term clinical wins, that's a signal for investors to recalibrate timelines on biotech AI valuations rather than a reason to abandon the thesis. Worth a read for anyone with capital in this vertical, less urgent for pure software builders.
The in-context, no-fine-tuning angle is the interesting part: it suggests foundation models can generalize across drug screening cohorts without per-patient retraining, which is the actual bottleneck in precision oncology pipelines today. Biotech-focused investors should track whether this generalizes beyond the four held-out datasets tested.
Four closed pharma deals in one summer is a concrete signal that biotech is moving past pilot purgatory into actual procurement for AI discovery tools. For investors, Bio x AI is one of the few application layers where enterprise customers are demonstrably paying real money rather than just running trials. Worth reading the full interview if you're evaluating vertical AI plays outside the usual SaaS categories.
Xaira's bet is that causal models need purpose-built experimental data rather than scraped observational data, a real methodological point for anyone doing ML in biotech. It's a narrow niche but a good read for investors tracking the AI-drug-discovery thesis beyond the hype cycle. Not urgent for general builders.
AI-assisted hypothesis generation finding actual wet-lab-validated results is the kind of proof point that moves AI-for-science from promise to track record. Still early and narrow, one finding in one cell model, but worth watching if you're investing in AI-driven biotech discovery pipelines.